HLB hits the intraday lower limit after FDA requests supplements for its new liver cancer drug
HLB 2026 year 7 month 10 day after the U.S. Food and Drug Administration (FDA) requested supplements for its new liver cancer drug, its share price hit the intraday lower limit. During the same period, E-Mart cut its target price by 15%, citing weak Starbucks sales, while Samsung SDS received an upgraded target price as its AI data center business came into view. KT&G was assigned a target price of 22ten thousand won.
HLB disclosed that it had been asked by the U.S. Food and Drug Administration (FDA) to supplement its application for a new liver cancer drug on 2026 year 7 month 10 day, and its share price hit the intraday lower limit following the news. From an investor's perspective, the possibility of delays to the new drug approval schedule and the submission of related materials is a direct risk factor.
7 month 9 day report on E-Mart cut its target price for E-Mart by 15%, citing weak Starbucks sales. The report stated that deteriorating store performance at Starbucks could put pressure on E-Mart's results.
A report released on the same day said Samsung SDS's target price was raised as its AI data center business came into view. The report cited positive signals related to the business's profitability development as the basis.
Regarding KT&G, 7month 9announcement highlighted the interim dividend and shareholder return policy, and a target price of 22ten thousand won was presented. The report stated that strengthening the dividend policy could affect the share price.
Regarding the market structure, it was pointed out that, when leveraged products are included, trading value becomes concentrated in some large-cap stocks, with 83% of trading value concentrated in a small number of stocks, 7month 9day. This observation shows the concentration of trading value in numerical terms.
The disclosures and reports released today are sending mixed signals by sector. Approval risks were highlighted in biotech, business visibility in IT and infrastructure, and concerns over sluggish sales in distribution and consumer sectors.
Investors should check the supplementary requirements, the basis for target-price changes, and dividend schedules presented in each company's official disclosures and reports.